JNJ

227.3

-0.24%↓

ISRG

507.91

-2.78%↓

ABT

106.03

+0.05%↑

MDT

100.97

+0.31%↑

133.13

-0.58%↓

JNJ

227.3

-0.24%↓

ISRG

507.91

-2.78%↓

ABT

106.03

+0.05%↑

MDT

100.97

+0.31%↑

133.13

-0.58%↓

JNJ

227.3

-0.24%↓

ISRG

507.91

-2.78%↓

ABT

106.03

+0.05%↑

MDT

100.97

+0.31%↑

133.13

-0.58%↓

JNJ

227.3

-0.24%↓

ISRG

507.91

-2.78%↓

ABT

106.03

+0.05%↑

MDT

100.97

+0.31%↑

133.13

-0.58%↓

JNJ

227.3

-0.24%↓

ISRG

507.91

-2.78%↓

ABT

106.03

+0.05%↑

MDT

100.97

+0.31%↑

133.13

-0.58%↓

Kodu・Aktsiate loetelu・Altimmune Inc

Altimmune Inc

Suletud

5.11

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

5.02

Max

5.47

Põhinäitajad
By Trading Economics
Sissetulek	3.1M -19M
Müük	5K
Kasumimarginaal	-380,280
Töötajad	59
EBITDA	4.4M -18M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+199.41% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	26. märts 2026

Turustatistika
By TradingEconomics
Turukapital	241M 591M
Eelmine avamishind	5.11
Eelmine sulgemishind	5.11

Tehniline skoor

By Trading Central

Kindlus

Bullish Evidence

5.365 / 6.0486 Toetus ja vastupanu

Altimmune Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

29. jaan 2026, 22:31 UTC

Tulu

KLA Posts Higher 2Q Profit On Product and Services Sales Growth

29. jaan 2026, 22:05 UTC

Tulu

Stryker Logs Higher 4Q Profit On Sales Gains

29. jaan 2026, 21:54 UTC

Tulu

Visa 1Q Sales Climb on Strong Holiday Shopping -- Update

29. jaan 2026, 21:36 UTC

Tulu

Visa 1Q Sales Climb on Strong Holiday Shopping

29. jaan 2026, 23:57 UTC

Omandamised, ülevõtmised, äriostud

Aluminum Corp. of China: to Hold 67% of Joint Venture With Rio Tinto

29. jaan 2026, 23:56 UTC

Omandamised, ülevõtmised, äriostud

Aluminum Corp. of China: Deal Valued at Roughly BRL4.69 Billion

29. jaan 2026, 23:53 UTC

Omandamised, ülevõtmised, äriostud

Aluminum Corp. of China Says It, Rio Tinto Propose to Buy 69% Stake in Companhia Brasileira de Aluminio S.A.

29. jaan 2026, 23:51 UTC

Tulu

Correction to Intel Earnings Article on Jan. 22 -- WSJ

29. jaan 2026, 23:49 UTC

Market Talk

Nikkei May Decline After Wall Street Tech Selloffs -- Market Talk

29. jaan 2026, 23:49 UTC

Market Talk

Gold Rises Amid Ongoing Iran Tensions -- Market Talk

29. jaan 2026, 23:47 UTC

Market Talk

Pro Medicus Looks Attractive Ahead of 1H Result -- Market Talk

29. jaan 2026, 23:35 UTC

Tulu

Apple Posts Blowout iPhone Sales on Surging China Demand -- 2nd Update

29. jaan 2026, 23:32 UTC

Market Talk

REA's 1H Result Could Jolt Share Price More Than Usual -- Market Talk

29. jaan 2026, 23:32 UTC

Market Talk

Global Equities Roundup: Market Talk

29. jaan 2026, 23:15 UTC

Market Talk

Tulu

Visa Says High Earners Still Lead Spending Growth -- Market Talk

29. jaan 2026, 22:27 UTC

Tulu

Sandisk Beats Earnings. The Stock Is Soaring. -- Barrons.com

29. jaan 2026, 22:27 UTC

Tulu

GE Vernova Gains After Earnings. Guidance Boost Was Enough to Lift the Stock. -- Barrons.com

29. jaan 2026, 22:12 UTC

Tulu

Visa Beats Expectations on Stronger Spending. The Stock Is Falling. -- Barrons.com

29. jaan 2026, 21:55 UTC

Tulu

Micron Stock Rises. Samsung Signals a 'Golden Era' for Memory Chips. -- Barrons.com

29. jaan 2026, 21:50 UTC

Market Talk

Tulu

Financial Services Roundup: Market Talk

29. jaan 2026, 21:50 UTC

Tulu

These Stocks Are Today's Movers: Microsoft, Meta, Tesla, Joby Aviation, SAP, Royal Caribbean, and More -- Barrons.com

29. jaan 2026, 21:50 UTC

Market Talk

Tulu

Health Care Roundup: Market Talk

29. jaan 2026, 21:50 UTC

Market Talk

Tulu

Auto & Transport Roundup: Market Talk

29. jaan 2026, 21:49 UTC

Tulu

Honeywell Delivers Solid Earnings Ahead of Its Corporate Breakup -- Barrons.com

29. jaan 2026, 21:46 UTC

Tulu

Apple Posts Blowout iPhone Sales on Surging China Demand -- Update

29. jaan 2026, 21:36 UTC

Tulu

Lockheed Martin Stock Jumps on Guidance and Government Missile Deal -- Barrons.com

29. jaan 2026, 21:32 UTC

Tulu

Visa Beats Expectations on Stronger Spending. The Stock Is Falling. -- Barrons.com

29. jaan 2026, 21:32 UTC

Tulu

Sandisk Beats Earnings. The Stock Is Soaring. -- Barrons.com

29. jaan 2026, 21:30 UTC

Tulu

Apple Posts Blowout IPhone Sales on Surging China Demand -- WSJ

29. jaan 2026, 21:30 UTC

Tulu

Apple 1Q Mac Rev $8.39B >AAPL

Võrdlus sarnastega

Hinnamuutus

Altimmune Inc Prognoos

Hinnasiht

By TipRanks

199.41% tõus

12 kuu keskmine prognoos

Keskmine 15.33 USD 199.41%

Kõrge 20 USD

Madal 12 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Altimmune Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Altimmune Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

5.365 / 6.0486Toetus ja vastupanu

Recent bullish events outweigh bearish events.

All events are bearish.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Altimmune Inc

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.